Sec Form 13D Filing - Novo Holdings A/S filing for LAVA THERAPEUTICS N V SHS (LVTX) - 2024-03-07

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 6)*

 

 

LAVA Therapeutics N.V.

(Name of Issuer)

 

 

Common Shares, par value $0.14 per share

(Title of Class of Securities)

N51517 105

(CUSIP Number)

Barbara Fiorini Due

Novo Holdings A/S

Tuborg Havnevej 19

Hellerup, Denmark DK-2900

+45 3527 6592

Copy to:

B. Shayne Kennedy, Esq.

Latham & Watkins LLP

650 Town Center Drive, 20th Floor

Costa Mesa, CA 92626

Telephone: (714) 540-1235

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

March 5, 2024

(Date of Event which Requires Filing of this Statement)

 

 

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is subject of this Schedule 13D, and is filing this statement because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. ☐

 

 

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties to whom copies are to be sent.

 

 

 

*

The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (the “Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 


CUSIP No.: N51517 105

 

 1.   

 Name of Reporting Person:

 

 Novo Holdings A/S

 2.  

Check the Appropriate Box if a Member of Group (See Instructions):

 (a) ☐  (b) ☐

 

 3.  

SEC Use Only:

 

 4.  

Source of Funds:

 

 WC

 5.  

Check if Disclosure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):

 

 ☐

 6.  

Citizenship or Place of Organization:

 

 Denmark

Number of

Shares

 Beneficially 

Owned By

Each

Reporting

Person

With:

 

   7.    

Sole Voting Power:

 

 0

   8.   

Shared Voting Power:

 

0

   9.   

Sole Dispositive Power:

 

 0

   10.   

Shared Dispositive Power:

 

 0

11.   

 Aggregate Amount Beneficially Owned by Each Reporting Person:

 

 0

12.  

 Check if the Aggregate Amount in Row (11) Excludes Certain Shares:

 

 ☐

13.  

 Percent of Class Represented By Amount In Row (11):

 

 0% (1)

14.  

 Type of Reporting Person:

 

 CO

 

(1)

Based upon 26,289,087 shares of the Issuer’s Common Shares outstanding as of September 30, 2023, as reported in the Issuer’s 6-K filed with the Securities and Exchange Commission (“SEC”) on November 16, 2023.

 

2


This amendment (“Amendment No. 6”) amends the Schedule 13D originally filed with the SEC on March 31, 2022, as subsequently amended by Amendment No. 1 filed September 30, 2022, Amendment No. 2 filed October 3, 2022, Amendment No. 3 filed February 24, 2023, Amendment No. 4 filed June 6, 2023, and Amendment No. 5 filed November 9, 2023 (collectively, the “Schedule”), to report and reflect that Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Shares in connection with sales. All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule.

 

Item 2.

Identity and Background

Item 2 is amended and replaced in its entirety as follows:

 

  (a)

Novo Holdings A/S, a Danish corporation, is an investment firm focused on life sciences and finance that is wholly owned by Novo Nordisk Foundation (the “Foundation”), a Danish commercial foundation. Novo Holdings A/S is the holding company in the group of Novo companies (currently comprised of Novo Nordisk A/S and Novozymes A/S) and is responsible for managing the Foundation’s assets, including its financial assets. Based on the governance structure of Novo Holdings A/S and the Foundation, the Foundation is not deemed to have any beneficial ownership of the securities of the Issuer held by Novo Holdings A/S.

The name of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on the updated Schedule I to this Amendment No. 6.

 

  (b)

The business address of both Novo Holdings A/S and the Foundation is Tuborg Havnevej 19, 2900 Hellerup, Denmark.

The residence or business address of each director and executive officer of both Novo Holdings A/S and the Foundation is set forth on the updated Schedule I to this Schedule 13D.

 

  (c)

Novo Holdings A/S, a holding company that is responsible for managing the Foundation’s assets, provides seed and venture capital to development stage companies and invests in well-established companies within the life science and biotechnology sector.

The Foundation is a Danish self-governing and profit-making foundation, whose objectives are to provide a stable basis for commercial and research activities undertaken by the group of Novo companies and to support scientific, humanitarian and social purposes through grants.

 

  (d)

Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I has been convicted in any criminal proceedings.

 

  (e)

Within the last five years, neither Novo Holdings A/S, the Foundation, nor any person named in the updated Schedule I was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

Item 3.

Source and Amount of Funds or Other Consideration

Item 3 amends and supplements Item 3 in the Schedule to reflect sales of the Issuer’s stock during the past 60 days, as follows:

On March 5, 2024, Novo Holdings A/S sold 1,496,815 shares at a weighted average price of $2.6473, with prices ranging from $2.25 to $3.34.

On March 6, 2024, Novo Holdings A/S sold 381,379 shares at a weighted average price of $2.3091, with prices ranging from $2.18 to $2.44.

 

3


Item 5.

Interest in Securities of the Issuer

Item 5 amends and supplements Item 5 in the Schedule as follows:

 

  (a)

Novo Holdings A/S beneficially owns 0 shares of Common Shares (the “Novo Shares”) representing approximately 0% of the Issuer’s outstanding shares of Common Shares, based upon 26,289,087 shares of the Issuer’s Common Shares outstanding as of September 30, 2023, as reported in the Issuer’s 6-K filed with the SEC on November 16, 2023.

 

  (b)

Novo Holdings A/S is a Danish corporation wholly owned by the Novo Nordisk Foundation. Novo Holdings A/S has the sole power to vote and dispose of the Novo Shares. Neither the Foundation nor any person listed on Schedule I has the power to direct the vote as to, or the disposition of the Novo Shares.

 

  (c)

Except as described herein, Novo Holdings A/S has not effected any transactions in the shares of the Issuer’s Common Shares and neither the Foundation nor any person listed on the Schedule I has effected any transactions in the Issuer’s Common Shares.

 

  (d)

Novo Holdings A/S does not know of any other person having the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Novo Shares.

 

  (e)

As of March 5, 2024, Novo Holdings A/S ceased to be a beneficial owner of more than five percent of the Issuer’s Common Shares.

 

4


SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Dated: March 7, 2024     Novo Holdings A/S
    /s/ Barbara Fiorini Due
    By:   Barbara Fiorini Due
    Its:   General Counsel, Finance & Operations


Schedule I

Information regarding each director and executive officer of both Novo Holdings A/S and the Novo Nordisk Foundation is set forth below.

 

Novo Holdings A/S

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Lars Rebien Sørensen,
Chair of the Board
   Via Volpini 35
53040 Cetona SI
Italy
   Professional Board Director    Denmark
Steen Riisgaard,
Vice Chair of the Board
   Hestetangsvej 155,
3520 Farum,
Denmark
   Professional Board Director    Denmark
Jean-Luc Butel,
Board Director
   235 Arcadia Road,
unit 10-3,
Singapore 289843
Singapore
  

Global Healthcare Advisor,

President, K8 Global Pte Ltd.

   Singapore
Jeppe Christiansen,
Board Director
   Classensgade 59, 5. th,
2100 Copenhagen Ø,
Denmark
   Chief Executive Officer,
Fondsmaeglerselskabet Maj Invest A/S
   Denmark
Francis Michael Cyprian Cuss,
Board Director
   111 Rippling Brook Way,
Bernardsville, NJ 07924
USA
   Biopharmaceutical Consultant   

United Kingdom

 

United States

Viviane Monges,
Board Director
  

Chemin de Craivavers 32,

1012 Lausanne,
Switzerland

   Professional Board Director    France
Henrik Poulsen,
Board Director
   Emiliekildevej 36
2930 Klampenborg
Denmark
  

Senior Advisor, A.P. Møller

Holding and Professional Board Director

   Denmark
Britt Meelby Jensen
Board Director
   Bukkeballevej 10
2960 Rungsted Kyst
Denmark
   Chief Executive Officer,
Ambu A/S
   Denmark
Susanne Antonie Schaffert
Board Director
   Am Eichenwald 18
91054 Erlangen
Germany
   Professional Board Director    Germany
Kasim Kutay,
Chief Executive Officer
   Bredgade 65, 3.tv.
1260 Copenhagen K.
Denmark
   Chief Executive Officer,
Novo Holdings A/S
   United Kingdom
Nigel Kevin Govett
Chief Financial Officer
  

Ingeborg Vænge 2,

2960 Rungsted Kyst
Denmark

   Chief Financial Officer,
Novo Holdings A/S
   United Kingdom


Novo Nordisk Foundation

Name, Title

  

Address

  

Principal Occupation

  

Citizenship

Lars Rebien Sørensen,

Chair of the Board

   Via Volpini 35
53040 Cetona SI
Italy
   Professional Board Director    Denmark

Lars Henrik Munch,

Vice Chair of the Board

  

Galionsvej 46

1437 København K

Denmark

   Professional Board Director    Denmark

Steen Riisgaard,

Board Director

   Hestetangsvej 155
3520 Farum
Denmark
   Professional Board Director    Denmark

Lars Henrik Fugger,

Board Director

  

72 Staunton Road,

Headington

OX3 7TP Oxford
Great Britain

   Professor, John Radcliffe Hospital, University of Oxford, Oxford, Great Britain    Denmark

Liselotte Højgaard,

Board Director

  

Grønningen 21, 4.

1270 København K

Denmark

   Professor    Denmark

Nana Sejbaek,

Board Director

  

Vinrankevej 3

2900 Hellerup

Denmark

   Operating Advisor with Goldman Sachs Asset Management and Professional Board Director    Denmark

Christopher Ashby Voigt

Board Director

  

57 Elizabeth Road

Belmont, MA 02478-3819

USA

   Professor of Advanced Biotechnology at Massachusetts Institute of Technology (MIT)    USA

Mads Boritz Grøn,

Board Director

  

Horsevænget 4

3400 Hillerød

Denmark

   Senior Lead Auditor,
Novo Nordisk A/S
   Denmark

Ole Jakob Müller,

Board Director

  

Borgmester Jensens A 11, 4.

00003
2100 Copenhagen Ø

Denmark

   Senior Environmental Specialist,
Novozymes A/S
   Denmark

Stig Strøbaek,

Board Director

   Furesøgårdsvej 2
3520 Farum
Denmark
   Electrician,
Novo Nordisk A/S
   Denmark

Mads Krogsgaard Thomsen,

Chief Executive Officer

  

Præstevejen 38

3230 Græsted

Denmark

   Chief Executive Officer,
Novo Nordisk Foundation
   Denmark